Dr. Derek Ellison was appointed chief operating officer, Eden Biodesign. The appointment is part of a management restructure, changing responsibilities for seven executive and senior management members to support the company’s expansion efforts.
 
Dr. Ellison, co-founder of Eden and previously vice president development and manufacturing, stated, “I am extremely excited to take on the role of COO. Being a co-founder of Eden, I have witnessed the company rise and develop, and am extremely proud of our move into new markets, while retaining our excellent reputation.”
 
Dr. Anita Bate, co-founder of Eden and previously science director, will become chief scientific officer. Dr. Bate’s responsibilities will include managing a transatlantic team tasked with exploring new opportunities for the company and evaluating new technologies.
 
Also, as Dr. Phil Ball moves from the UK to the U.S. offices, he will take up the role of technical director and will support Roger Lias, president of Eden Biodesign, Inc. (the U.S. subsidiary of Eden).
 
Additional promotions and changes in responsibility include:  Dr. David Simpson, process development manager, Dr. Mandy Shipman, biopharm development consultant, and Gina Wenham will take on responsibility for the Analytical Development team alongside Quality Control and Alison Justice has been promoted to QA director.
 
Dr. Crawford Brown, chief executive officer and founder of Eden Biodesign commented, “We are delighted to announce these strategic changes to the executive and senior management team, which will maintain Eden’s position of leadership in the bioprocessing marketplace and which demonstrates our commitment to U.S. development and our international focus as demand continues to grow.”